JETEMA Trademark

Trademark Overview


On Friday, May 3, 2019, a trademark application was filed for JETEMA with the United States Patent and Trademark Office. The USPTO has given the JETEMA trademark a serial number of 79260875. The federal status of this trademark filing is REGISTERED as of Tuesday, June 9, 2020. This trademark is owned by JETEMA CO., LTD.. The JETEMA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for urogenital organs; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; ophthalmic preparations; allergy medications; pharmaceutical agents for epidermis; pharmaceutical preparations acting on the central nervous system; analgesics; pharmaceutical preparations for respiratory organs; medicines for dental purposes; Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; st...
jetema

General Information


Serial Number79260875
Word MarkJETEMA
Filing DateFriday, May 3, 2019
Status700 - REGISTERED
Status DateTuesday, June 9, 2020
Registration Number6071731
Registration DateTuesday, June 9, 2020
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, March 24, 2020

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and Servicespharmaceutical agents affecting sensory organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for urogenital organs; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; ophthalmic preparations; allergy medications; pharmaceutical agents for epidermis; pharmaceutical preparations acting on the central nervous system; analgesics; pharmaceutical preparations for respiratory organs; medicines for dental purposes; Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Translation of Words in MarkThe wording "JETEMA" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 20, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameJETEMA CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressGangwon-do
KR

Party NameJETEMA CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGangwon-do
KR

Party NameJETEMA CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGangwon-do
KR

Trademark Events


Event DateEvent Description
Saturday, October 17, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, September 29, 2020FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, September 29, 2020FINAL DISPOSITION PROCESSED
Wednesday, September 9, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 9, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, March 24, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 24, 2020PUBLISHED FOR OPPOSITION
Wednesday, March 4, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 19, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 30, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 29, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 29, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 29, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, August 23, 2019REFUSAL PROCESSED BY IB
Friday, August 2, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, August 1, 2019REFUSAL PROCESSED BY MPU
Tuesday, July 16, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, July 15, 2019NON-FINAL ACTION WRITTEN
Monday, July 15, 2019NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Friday, July 12, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, July 11, 2019NON-FINAL ACTION WRITTEN
Thursday, July 11, 2019ASSIGNED TO EXAMINER
Tuesday, June 25, 2019APPLICATION FILING RECEIPT MAILED
Thursday, June 20, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, June 13, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB